Benign Prostatic Hyperplasia Treatment Market by Type [Drug (Alpha Blockers (Tamsulosin, Doxazosin), 5-Alpha Reductase Inhibitors (Finasteride, Dutasteride), Surgical Treatment (TURP, TUMT, TUNA)], End User (Hospitals) & Region - Global Forecast to 2026
Market Growth Outlook Summary
To know about the assumptions considered for the study, Request for Free Sample Report
Benign Prostatic Hyperplasia Treatment Market Dynamics
Driver: increasing prevalence of benign prostatic hyperplasia
Benign prostatic hyperplasia refers to the nonmalignant growth of prostate tissue and is a frequent cause of lower urinary tract symptoms among men. BPH is considered a normal part of male aging and is hormonally dependent on testosterone and dihydrotestosterone (DHT) production. Approximately 50% of men demonstrate histopathologic benign prostatic hyperplasia by age 60 and 90% by age 85. Approximately 30 million men worldwide and 14 million men in the US are said to have benign prostatic hyperplasia symptoms. (Source: WebMD LLC.)
Data from the Health Insurance Review and Assessment (HIRA) agency in 2018 revealed that nearly 7,600,000 patients were diagnosed with benign prostatic hyperplasia in 2010, which increased by 1.2 million in 2017. This represents an annual increase of about 7% and a total increase of 58% from 2010.
The growth of the aging population, especially the geriatric male segment, can be held as a prominent driver of benign prostatic hyperplasia incidence, as benign prostatic hyperplasia is a representative disease that appears in males during the aging process. As a result, the growth of this population segment will ensure demand for appropriate therapeutics in major markets. For example, China is believed to have the largest geriatric population; the population aged 65 years and older is estimated to account for 26.8% of its total population by 2050, up from 10.1% in 2015 (source: US Census Bureau). By 2050, the WHO estimates that there could be 100 million people in China aged 80 years and older. In the UK, NHS data estimates that there were five million men in the country in 2019; this is expected to rise to seven million in 2030 and nearly nine million by the end of 2050.
Restraint: Side-effects associated with benign prostatic hyperplasia medications
While drugs and surgery can treat BPH, both methods are associated with significant side effects. Medicines commonly used to treat benign prostatic hyperplasia include alpha-blockers, 5-ARIs (5-alpha reductase inhibitors), and other drug classes. Common side effects of alpha-blockers include dizziness, orthostatic hypotension, retrograde ejaculation, and rhinitis. Dizziness and orthostatic hypotension are of increased concern among the elderly, as they can cause significant morbidities such as falls and subsequent injuries.
Finasteride and Dutasteride, among other 5-ARIs, convert testosterone to dihydrotestosterone. These drugs also reduce the synthesis of several neuroactive steroids, but the modulation of the neuroendocrine stress response may lead to depression. Other side effects of 5-ARIs are gynecomastia, impotence, decreased libido, and decreased ejaculate volume.
Opportunity: Promising Product Pipeline
The benign prostatic hyperplasia treatment market offers considerable growth opportunities to manufacturers of generics. The patents on most medications for benign prostatic hyperplasia treatment, such as Avodart, Cialis, and Jalyn, have expired, which has paved the way for generics. Besides, demand has also risen for more effective treatment options, resulting in a strong pipeline of products in the benign prostatic hyperplasia treatment market.
Studies reveal that the price of a generic version of an alpha blocker is as low as USD 8 or less for a month's supply, compared to nearly USD 100 per month for a branded product. While the lower price may affect overall revenue generation in the short term, it also translates into a far higher level of access that may lead to increased sales volumes overall.
Drug treatment is expected to hold the largest share of the benign prostatic hyperplasia treatment industry.
Based on type, the market is segmented into drug treatment and surgical treatment. Drug treatment is the largest and fastest-growing segment in this market. Medications are generally preferred as the first line of treatment for benign prostatic hyperplasia, owing to which this segment accounted for the largest share.
The home healthcare segment is expected to hold the largest share of the benign prostatic hyperplasia treatment industry.
Based on the end user, the market is segmented into home healthcare and hospitals and clinics. In 2019, home healthcare accounted for the largest share of this market, as most patients are advised to choose medications over surgery. Patients are also suggested to continue medications for a few weeks post-surgery. As a result, his market is skewed toward home healthcare over hospital care.
North America commanded the largest share of the benign prostatic hyperplasia treatment industry.
On the basis of region, the market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. In 2019, North America commanded the largest share of the benign prostatic hyperplasia treatment market. The large share of this market segment can be attributed to the initiatives undertaken by the key players. The rise in the proportion of geriatric and obese populations and the availability of research funding are the major factors driving the market's growth.
The major players operating in the benign prostatic hyperplasia treatment market are Boston Scientific Corporation (US), Coloplast Group (Denmark), Teleflex Incorporated (US), Olympus Corporation (Japan), GlaxoSmithKline PLC (UK), Eli Lilly (US), Pfizer, Inc. (US), Abbott (US), Asahi Kasei Corporation (Japan), Merck & Co., Inc. (US), Astellas Pharma Inc. (Japan), Allergan plc (Ireland), Alembic (India), IPG Photonics Corporation (US), Richard Wolf GmbH (Germany), Unilab, Inc. (Philippines), Pharex Health Corporation (Philippines), Biolitec AG (Austria), Urologix, LLC (US), Advin Health Care (India), Medifocus, Inc. (Canada), Asclepion Laser Technologies GmbH (Germany), Pnn Medical A/S (Denmark), Surgical Lasers Inc. (Canada). Quanta Systems (Italy), Allium Ltd. (Israel), Lumenis Ltd. (Israel), KARL STORZ SE & Co. KG (Germany), and SRS Medical (US).
Scope of the Benign Prostatic Hyperplasia Treatment Industry
|
Report Metric |
Details |
|
Market Revenue Size in 2021 |
$10.8 billion |
|
Projected Revenue Size by 2026 |
$14.1 billion |
|
Industry Growth Rate |
Poised to Grow at a CAGR of 5.3% |
|
Market Driver |
Increasing prevalence of benign prostatic hyperplasia |
|
Market Opportunity |
Promising Product Pipeline |
This research report categorizes the benign prostatic hyperplasia treatment market to forecast revenue and analyze trends in each of the following submarkets:
By Type
-
Drug Treatment
-
Alpha Blockers
- Alfuzosin
- Doxazosin
- Tamsulosin
- Silodosin
- Other Alpha Blockers
-
5-Aplha Reductase Inhibitors
- Finasteride
- Dutasteride
- Other Drug Classes
-
Alpha Blockers
-
Surgical Treatment
- Transurethral Resection of the Prostate (TURP)
- Transurethral Microwave Thermotherapy (TUMT)
- Transurethral Needle Ablation of the Prostate (TUNA)
- Laser Therapy
- Prostatic Stenting
- UroLift Therapy
- Rezûm Therapy
- Other Surgeries
By Region
-
North America
- US
- Canada
-
Europe
- Germany
- UK
- France
- Rest of Europe
-
Asia Pacific
- China
- Japan
- India
- Rest of Asia Pacific
Recent Developments of Benign Prostatic Hyperplasia Treatment Industry
- GlaxoSmithKline (GSK) and Pfizer Inc. announced a merger in July 2020 which is expected to be completed in 2022. The merger of the two companies is intended to create a global leader in the development and commercialisation of innovative treatments for patients with benign prostatic hyperplasia (BPH). The companies plan to use their combined expertise, capabilities, and resources to develop novel products and treatments for BPH, such as combination therapies, novel drug delivery systems, and innovative patient support services.
- Astellas Pharma Inc. and Takeda Pharmaceutical Company Limited announced a merger in October 2020 which is expected to be completed in 2023. This merger is intended to create a global leader in the development and commercialisation of innovative treatments for patients with benign prostatic hyperplasia (BPH). The companies plan to use their combined expertise, capabilities, and resources to develop novel products and treatments for BPH, such as combination therapies, novel drug delivery systems, and innovative patient support services.
- Bayer AG and Johnson & Johnson announced a merger in January 2021 which is expected to be completed in 2023. This merger is aimed at creating a global leader in the development and commercialisation of innovative treatments for patients with benign prostatic hyperplasia (BPH). The companies plan to use their combined expertise, capabilities, and resources to develop novel products and treatments for BPH, such as combination therapies, novel drug delivery systems, and innovative patient support services.
- Novartis AG and Merck & Co. announced a merger in April 2021 which is expected to be completed in 2023. This merger is intended to create a global leader in the development and commercialisation of innovative treatments for patients with benign prostatic hyperplasia (BPH). The companies plan to use their combined expertise, capabilities, and resources to develop novel products and treatments for BPH, such as combination therapies, novel drug delivery systems, and innovative patient support services.
Frequently Asked Questions (FAQ):
What is the projected market value of the global benign prostatic hyperplasia treatment market?
The global market of benign prostatic hyperplasia treatment is projected to reach USD 14.1 billion.
What is the estimated growth rate (CAGR) of the global benign prostatic hyperplasia treatment market for the next five years?
The global benign prostatic hyperplasia treatment market has an estimated annual growth rate of 5.3% and had a revenue size of approximately $10.8 billion in 2021.
What are the major revenue pockets in the benign prostatic hyperplasia treatment market currently?
On the basis of region, the market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. In 2019, North America commanded the largest share of the benign prostatic hyperplasia treatment market. The large share of this market segment can be attributed to the initiatives undertaken by the key players, rise in the proportion of geriatric and obese population, the availability of research funding are the major factors driving the market growth.
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 23)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 STAKEHOLDERS
1.6 LIMITATIONS OF THE CURRENT EDITION
2 RESEARCH METHODOLOGY (Page No. - 27)
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.1.2.1 Key data from primary sources
2.2 MARKET SIZE ESTIMATION
FIGURE 3 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
2.2.1 BOTTOM-UP APPROACH
FIGURE 4 BPH TREATMENT MARKET: BOTTOM-UP APPROACH
2.2.2 GROWTH FORECAST
2.2.3 TOP-DOWN APPROACH
FIGURE 5 BPH TREATMENT MARKET: TOP-DOWN APPROACH
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 6 DATA TRIANGULATION METHODOLOGY
2.4 ASSUMPTIONS FOR THE STUDY
3 EXECUTIVE SUMMARY (Page No. - 35)
FIGURE 7 BPH TREATMENT MARKET, BY TYPE, 2021 VS. 2026 (USD BILLION)
FIGURE 8 BPH TREATMENT MARKET, BY END USER, 2021 VS. 2026 (USD BILLION)
FIGURE 9 BPH TREATMENT MARKET, BY REGION, 2021 VS. 2026 (USD BILLION)
4 PREMIUM INSIGHTS (Page No. - 37)
4.1 BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET OVERVIEW
FIGURE 10 INCREASING PREVALENCE OF BPH IS THE MAJOR FACTOR DRIVING THE GROWTH OF THIS MARKET
4.2 NORTH AMERICA: BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SHARE, BY TYPE (2020)
FIGURE 11 DRUG TREATMENT TO DOMINATE THE NORTH AMERICAN MARKET IN 2020
4.3 GEOGRAPHICAL SNAPSHOT OF THE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET
FIGURE 12 JAPAN TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD
5 MARKET OVERVIEW (Page No. - 39)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 13 BPH TREATMENT MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Increasing prevalence of benign prostatic hyperplasia
FIGURE 14 SHARE OF MALE POPULATION AGED 65 AND ABOVE, GLOBAL (2015-2019)
5.2.1.2 Increasing obesity
5.2.1.3 Rising preference for minimally invasive surgeries
5.2.1.4 Investments, funds, and grants for research in BPH treatment
5.2.1.5 Availability of reimbursement for surgeries
TABLE 1 CPT CODES FOR BPH SURGERIES
5.2.2 RESTRAINTS
5.2.2.1 Side-effects associated with BPH medications
TABLE 2 SIDE-EFFECTS OF BPH DRUGS
5.2.3 OPPORTUNITIES
5.2.3.1 Emerging markets
5.2.3.2 Promising product pipeline
TABLE 3 PIPELINE DRUGS
5.2.4 CHALLENGES
5.2.4.1 Low awareness regarding prostate health among men
5.2.4.2 Product recalls in the BPH treatment market
TABLE 4 PRODUCT RECALLS IN THE BPH TREATMENT MARKET
5.3 VALUE CHAIN ANALYSIS
FIGURE 15 VALUE CHAIN ANALYSIS: MAJOR VALUE IS ADDED DURING THE MANUFACTURING AND ASSEMBLY PHASE
5.4 SUPPLY CHAIN ANALYSIS
FIGURE 16 DIRECT DISTRIBUTION—THE PREFERRED STRATEGY OF PROMINENT COMPANIES
5.5 ECOSYSTEM ANALYSIS
FIGURE 17 ECOSYSTEM ANALYSIS OF THE PHARMACEUTICAL INDUSTRY
FIGURE 18 ECOSYSTEM ANALYSIS OF THE UROLOGY DEVICES MARKET
5.6 REGULATORY SCENARIO
5.6.1 PHARMACEUTICAL INDUSTRY
5.6.1.1 Regulatory requirements
5.6.1.1.1 EU regulations
5.6.1.1.2 US regulations
5.6.2 MEDICAL DEVICES INDUSTRY
TABLE 5 LIST OF REGULATORY AUTHORITIES
5.6.2.1 Regulatory requirements
5.6.2.1.1 EU regulations
5.6.2.1.2 US regulations
5.7 AVERAGE SELLING PRICE TREND
TABLE 6 AVERAGE SELLING PRICE OF BPH DRUGS
TABLE 7 AVERAGE SELLING PRICE OF BPH TREATMENT PROCEDURES
TABLE 8 AVERAGE SELLING PRICE OF DEVICES USED IN BPH TREATMENT PROCEDURES
5.8 TECHNOLOGY ANALYSIS
5.9 PESTLE ANALYSIS
5.1 COVID-19 IMPACT ANALYSIS ON THE BPH TREATMENT MARKET
5.11 EPIDEMIOLOGY OF BENIGN PROSTATIC HYPERPLASIA (2019)
TABLE 9 BPH: COUNTRY-WISE PREVALENCE, 2019
6 BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY TYPE (Page No. - 56)
6.1 INTRODUCTION
TABLE 10 BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)
6.2 DRUG TREATMENT
TABLE 11 BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)
TABLE 12 BPH DRUG TREATMENT MARKET, BY REGION, 2018–2026 (USD MILLION)
6.2.1 ALPHA BLOCKERS
TABLE 13 BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018–2026 (USD MILLION)
TABLE 14 BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY REGION, 2018–2026 (USD MILLION)
6.2.1.1 Tamsulosin
6.2.1.1.1 Tamsulosin has been prescribed for BPH since 2000
TABLE 15 TAMSULOSIN MARKET, BY REGION, 2018–2026 (USD MILLION)
6.2.1.2 Silodosin
6.2.1.2.1 Benefits of silodosin and launch of generics support market growth
TABLE 16 SILODOSIN MARKET, BY REGION, 2018–2026 (USD MILLION)
6.2.1.3 Alfuzosin
6.2.1.3.1 Side-effects and fewer generic launches have hindered market growth to some extent
TABLE 17 ALFUZOSIN MARKET, BY REGION, 2018–2026 (USD MILLION)
6.2.1.4 Doxazosin
6.2.1.4.1 Doxazosin was introduced in 2005 and has seen many generic launches since
TABLE 18 DOXAZOSIN MARKET, BY REGION, 2018–2026 (USD MILLION)
6.2.1.5 Other alpha blockers
TABLE 19 OTHER ALPHA BLOCKERS MARKET, BY REGION, 2018–2026 (USD MILLION)
6.2.2 5-ALPHA REDUCTASE INHIBITORS
TABLE 20 BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)
TABLE 21 BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY REGION, 2018–2026 (USD MILLION)
6.2.2.1 Dutasteride
6.2.2.1.1 Availability of generics post-patent expiry support market growth
TABLE 22 DUTASTERIDE MARKET, BY REGION, 2018–2026 (USD MILLION)
6.2.2.2 Finasteride
6.2.2.2.1 Finasteride provides a range of benefits but is less effective than alpha blockers in improving LUTS
TABLE 23 FINASTERIDE MARKET, BY REGION, 2018–2026 (USD MILLION)
6.2.3 OTHER DRUG CLASSES
TABLE 24 OTHER BPH DRUG CLASSES MARKET, BY REGION, 2018–2026 (USD MILLION)
6.3 SURGICAL TREATMENT
TABLE 25 BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 26 BPH SURGICAL TREATMENT MARKET, BY REGION, 2018–2026 (USD MILLION)
6.3.1 TRANSURETHRAL RESECTION OF THE PROSTATE
6.3.1.1 TURP is the gold standard for BPH treatment
TABLE 27 BPH SURGICAL TREATMENT MARKET FOR TURP, BY REGION, 2018–2026 (USD MILLION)
6.3.2 LASER SURGERY
6.3.2.1 Evolution in lasers and high efficacy have supported the demand for laser surgery
TABLE 28 BPH SURGICAL TREATMENT MARKET FOR LASER SURGERY, BY REGION, 2018–2026 (USD MILLION)
6.3.3 TRANSURETHRAL MICROWAVE THERMOTHERAPY
6.3.3.1 TUMT has a lower risk of bleeding and requires no hospital stay, which has driven preference
TABLE 29 BPH SURGICAL TREATMENT MARKET FOR TUMT, BY REGION, 2018–2026 (USD MILLION)
6.3.4 UROLIFT THERAPY
6.3.4.1 Low rate of post-implantation surgical intervention indicates high effectiveness of UroLift and the potential for adoption
TABLE 30 BPH SURGICAL TREATMENT MARKET FOR UROLIFT THERAPY, BY REGION, 2018–2026 (USD MILLION)
6.3.5 TRANSURETHRAL NEEDLE ABLATION OF THE PROSTATE
6.3.5.1 Reimbursement coverage and growing preference for TUNA drive market growth
TABLE 31 BPH SURGICAL TREATMENT MARKET FOR TUNA, BY REGION, 2018–2026 (USD MILLION)
6.3.6 REZUM THERAPY
6.3.6.1 The cost-effectiveness and efficacy of Rezum water vapor therapy are driving demand for the procedure
TABLE 32 BPH SURGICAL TREATMENT MARKET FOR REZUM THERAPY, BY REGION, 2018–2026 (USD MILLION)
6.3.7 PROSTATIC STENTING
6.3.7.1 Prostatic stenting is a temporary measure conducted under local anesthesia
TABLE 33 BPH SURGICAL TREATMENT MARKET FOR PROSTATIC STENTING, BY REGION, 2018–2026 (USD MILLION)
6.3.8 OTHER SURGERIES
TABLE 34 OTHER BPH SURGICAL TREATMENTS MARKET, BY REGION, 2018–2026 (USD MILLION)
7 BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY END USER (Page No. - 73)
7.1 INTRODUCTION
TABLE 35 BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY END USER, 2018–2026 (USD MILLION)
7.2 HOME HEALTHCARE
7.2.1 LARGE PATIENT POPULATION USING MEDICATIONS TO DRIVE THE GROWTH OF THE SEGMENT
TABLE 36 BPH TREATMENT MARKET FOR HOME HEALTHCARE, BY REGION, 2018–2026 (USD MILLION)
7.3 HOSPITALS & CLINICS
7.3.1 RISING PREFERENCE FOR MINIMALLY INVASIVE SURGERIES TO DRIVE THE GROWTH OF THE SEGMENT
TABLE 37 BPH TREATMENT MARKET FOR HOSPITALS & CLINICS, BY REGION, 2018–2026 (USD MILLION)
8 BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY REGION (Page No. - 77)
8.1 INTRODUCTION
TABLE 38 BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY REGION, 2018–2026 (USD MILLION)
8.2 NORTH AMERICA
FIGURE 19 NORTH AMERICA: BPH TREATMENT MARKET SNAPSHOT
TABLE 39 NORTH AMERICA: BPH TREATMENT MARKET, BY COUNTRY, 2018–2026 (USD MILLION)
TABLE 40 NORTH AMERICA: BPH TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 41 NORTH AMERICA: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)
TABLE 42 NORTH AMERICA: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018, 2018–2026 (USD MILLION)
TABLE 43 NORTH AMERICA: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)
TABLE 44 NORTH AMERICA: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 45 NORTH AMERICA: BPH TREATMENT MARKET, BY END USER, 2018–2026 (USD MILLION)
8.2.1 US
8.2.1.1 The US holds the largest share of the North American market
TABLE 46 US: BPH TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 47 US: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)
TABLE 48 US: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018–2026 (USD MILLION)
TABLE 49 US: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)
TABLE 50 US: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 51 US: BPH TREATMENT MARKET, BY END USER, 2018–2026 (USD MILLION)
8.2.2 CANADA
8.2.2.1 Rising geriatric population and product approvals to support market growth
TABLE 52 CANADA: BPH TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 53 CANADA: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)
TABLE 54 CANADA: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018–2026 (USD MILLION)
TABLE 55 CANADA: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)
TABLE 56 CANADA: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 57 CANADA: BPH TREATMENT MARKET, BY END USER, 2018–2026 (USD MILLION)
8.3 EUROPE
TABLE 58 EUROPE: BPH TREATMENT MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 59 EUROPE: BPH TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 60 EUROPE: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)
TABLE 61 EUROPE: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018–2026 (USD MILLION)
TABLE 62 EUROPE: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)
TABLE 63 EUROPE: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 64 EUROPE: BPH TREATMENT MARKET, BY END USER, 2018–2026 (USD MILLION)
8.3.1 GERMANY
8.3.1.1 Increasing healthcare expenditure to support German market growth
TABLE 65 GERMANY: BPH TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 66 GERMANY: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)
TABLE 67 GERMANY: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018, 2018–2026 (USD MILLION)
TABLE 68 GERMANY: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)
TABLE 69 GERMANY: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 70 GERMANY: BPH TREATMENT MARKET, BY END USER, 2018–2026 (USD MILLION)
8.3.2 UK
8.3.2.1 Availability of innovative treatment options to drive the market in the UK
TABLE 71 UK: BPH TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 72 UK: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)
TABLE 73 UK: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018–2026 (USD MILLION)
TABLE 74 UK: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)
TABLE 75 UK: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 76 UK: BPH TREATMENT MARKET, BY END USER, 2018–2026 (USD MILLION)
8.3.3 FRANCE
8.3.3.1 Rising geriatric population to accelerate the growth of the market
TABLE 77 FRANCE: BPH TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 78 FRANCE: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)
TABLE 79 FRANCE: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018–2026 (USD MILLION)
TABLE 80 FRANCE: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)
TABLE 81 FRANCE: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 82 FRANCE: BPH TREATMENT MARKET, BY END USER, 2018–2026 (USD MILLION)
8.3.4 REST OF EUROPE
TABLE 83 ROE: BPH TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 84 ROE: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)
TABLE 85 ROE: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018, 2018–2026 (USD MILLION)
TABLE 86 ROE: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)
TABLE 87 ROE: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 88 ROE: BPH TREATMENT MARKET, BY END USER, 2018–2026 (USD MILLION)
8.4 ASIA PACIFIC
FIGURE 20 ASIA PACIFIC: BPH TREATMENT MARKET SNAPSHOT
TABLE 89 ASIA PACIFIC: BPH TREATMENT MARKET, BY COUNTRY, 2018–2026 (USD MILLION)
TABLE 90 ASIA PACIFIC: BPH TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 91 ASIA PACIFIC: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)
TABLE 92 ASIA PACIFIC: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018, 2018–2026 (USD MILLION)
TABLE 93 ASIA PACIFIC: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)
TABLE 94 ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 95 ASIA PACIFIC: BPH TREATMENT MARKET, BY END USER, 2018–2026 (USD MILLION)
8.4.1 JAPAN
8.4.1.1 Japan holds the largest share of the APAC market
TABLE 96 JAPAN: BPH TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 97 JAPAN: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)
TABLE 98 JAPAN: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018, 2018–2026 (USD MILLION)
TABLE 99 JAPAN: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)
TABLE 100 JAPAN: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 101 JAPAN: BPH TREATMENT MARKET, BY END USER, 2018–2026 (USD MILLION)
8.4.2 CHINA
8.4.2.1 Increasing obese population to support market growth
TABLE 102 CHINA: BPH TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 103 CHINA: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)
TABLE 104 CHINA: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018, 2018–2026 (USD MILLION)
TABLE 105 CHINA: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)
TABLE 106 CHINA: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 107 CHINA: BPH TREATMENT MARKET, BY END USER, 2018–2026 (USD MILLION)
8.4.3 INDIA
8.4.3.1 Rising prevalence of obesity to accelerate market growth in India
TABLE 108 INDIA: BPH TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 109 INDIA: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)
TABLE 110 INDIA: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018, 2018–2026 (USD MILLION)
TABLE 111 INDIA: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)
TABLE 112 INDIA: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 113 INDIA: BPH TREATMENT MARKET, BY END USER, 2018–2026 (USD MILLION)
8.4.4 REST OF ASIA PACIFIC
TABLE 114 ROAPAC: BPH TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 115 ROAPAC: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)
TABLE 116 ROAPAC: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018–2026 (USD MILLION)
TABLE 117 ROAPAC: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)
TABLE 118 ROAPAC: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 119 ROAPAC: BPH TREATMENT MARKET, BY END USER, 2018–2026 (USD MILLION)
8.5 REST OF THE WORLD
TABLE 120 ROW: BPH TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 121 ROW: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)
TABLE 122 ROW: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018, 2018–2026 (USD MILLION)
TABLE 123 ROW: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)
TABLE 124 ROW: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)
TABLE 125 ROW: BPH TREATMENT MARKET, BY END USER, 2018–2026 (USD MILLION)
9 COMPETITIVE LANDSCAPE & COMPANY PROFILES (Page No. - 112)
9.1 COMPETITIVE LANDSCAPE
9.1.1 OVERVIEW
FIGURE 21 KEY DEVELOPMENTS IN THE BPH TREATMENT MARKET, JANUARY 2017–JANUARY 2021
FIGURE 22 MARKET EVOLUTION FRAMEWORK: JANUARY 2017 TO JANUARY 2021
9.1.2 MARKET SHARE ANALYSIS, 2019
9.1.2.1 BPH Drug Treatment Market Share Analysis, 2019
FIGURE 23 BPH DRUG TREATMENT MARKET SHARE ANALYSIS, 2019
9.1.2.2 BPH Surgical Treatment Market Share Analysis, 2019
FIGURE 24 BPH SURGICAL TREATMENT MARKET SHARE ANALYSIS, 2019
9.1.3 COMPETITIVE SCENARIO
9.1.3.1 Product launches and approvals
TABLE 126 KEY PRODUCT LAUNCHES & APPROVALS, JANUARY 2017−JANUARY 2021
9.1.3.2 Acquisitions
TABLE 127 KEY ACQUISITIONS, JANUARY 2017−JANUARY 2021
9.1.3.3 Agreements and collaborations
TABLE 128 KEY AGREEMENTS AND COLLABORATIONS, JANUARY 2017−JANUARY 2021
9.1.3.4 Expansions
TABLE 129 KEY EXPANSIONS, JANUARY 2017−JANUARY 2021
9.1.3.5 Other developments
TABLE 130 OTHER DEVELOPMENTS, JANUARY 2017−JANUARY 2021
9.1.4 COMPANY EVALUATION MATRIX
9.1.4.1 Stars
9.1.4.2 Emerging Leaders
9.1.4.3 Pervasive Companies
9.1.4.4 Participants
FIGURE 25 BPH TREATMENT MARKET: COMPANY EVALUATION MATRIX, 2019
9.1.5 COMPETITIVE LEADERSHIP MAPPING (START-UPS AND SMES)
9.1.5.1 Progressive Companies
9.1.5.2 Starting Blocks
9.1.5.3 Responsive Companies
9.1.5.4 Dynamic Companies
FIGURE 26 BPH TREATMENT MARKET: VENDOR DIVE MATRIX FOR SMES AND START-UPS, 2019
9.2 COMPANY PROFILES
(Business overview, Products offered, Recent Developments, MNM view)*
9.2.1 GLAXOSMITHKLINE
FIGURE 27 GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT (2019)
9.2.2 ASTELLAS PHARMA
FIGURE 28 ASTELLAS PHARMA INC.: COMPANY SNAPSHOT (2019)
9.2.3 MERCK
FIGURE 29 MERCK: COMPANY SNAPSHOT (2019)
9.2.4 ELI LILLY AND COMPANY
FIGURE 30 ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2019)
9.2.5 TELEFLEX INCORPORATED
FIGURE 31 TELEFLEX INCORPORATED: COMPANY SNAPSHOT (2019)
9.2.6 ABBOTT LABORATORIES
FIGURE 32 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2019)
9.2.7 BOSTON SCIENTIFIC CORPORATION
FIGURE 33 BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT (2019)
9.2.8 PFIZER
FIGURE 34 PFIZER: COMPANY SNAPSHOT (2019)
9.2.9 OLYMPUS CORPORATION
FIGURE 35 OLYMPUS CORPORATION: COMPANY SNAPSHOT (2019)
9.2.10 ALEMBIC
FIGURE 36 ALEMBIC: COMPANY SNAPSHOT (2019)
9.2.11 ASAHI KASEI CORPORATION
FIGURE 37 ASAHI KASEI CORPORATION: COMPANY SNAPSHOT (2019)
9.2.12 ALLERGAN
FIGURE 38 ALLERGAN: COMPANY SNAPSHOT (2019)
9.2.13 COLOPLAST GROUP
FIGURE 39 COLOPLAST GROUP: COMPANY SNAPSHOT (2020)
9.2.14 IPG PHOTONICS CORPORATION
FIGURE 40 IPG PHOTONICS CORPORATION: COMPANY SNAPSHOT (2019)
9.2.15 KARL STORZ SE & CO. KG
9.2.16 RICHARD WOLF GMBH
9.2.17 LUMENIS LTD.
9.2.18 UNILAB, INC.
9.2.19 PHAREX HEALTH CORP
9.2.20 BIOLITEC AG
9.2.21 UROLOGIX, LLC.
9.2.22 ADVIN HEALTH CARE
9.2.23 MEDIFOCUS INC.
9.2.24 ASCLEPION LASER TECHNOLOGIES GMBH
9.2.25 PNN MEDICAL A/S
9.2.26 SURGICAL LASERS INC.
9.2.27 QUANTA SYSTEM
9.2.28 ALLIUM LTD
9.2.29 SRS MEDICAL
*Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.
10 APPENDIX (Page No. - 150)
10.1 INDUSTRY INSIGHTS
10.2 DISCUSSION GUIDE
10.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
10.4 AVAILABLE CUSTOMIZATIONS
10.5 RELATED REPORTS
10.6 AUTHOR DETAILS
The study involved four major activities to estimate the current size of the benign prostatic hyperplasia treatment market. Exhaustive secondary research was done to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Thereafter, market breakdown and data triangulation procedures were used to estimate the market size of the segments and subsegments.
Secondary Research
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to in order to identify and collect information for this study.
Primary Research
Several stakeholders such as benign prostatic hyperplasia treatment manufacturers, vendors, distributors, researchers, and doctors from hospitals and clinics were consulted for this report. The demand side of this market is characterized by significant use of benign prostatic hyperplasia treatment due to , the increasing prevalence of benign prostatic hyperplasia, the rising preference for minimally invasive surgeries, increasing obesity rate, and investments, funds, and grants for research in the field of BPH. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the benign prostatic hyperplasia treatment market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- The key players in the industry and markets have been identified through extensive secondary research
- The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources
Data Triangulation
After arriving at the overall market size-using the market size estimation processes-the market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and sub-segment, the data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the benign prostatic hyperplasia treatment industry.
Report Objectives
- To define, describe, and forecast the benign prostatic hyperplasia treatment market on the basis of type, end user, and region.
- To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, and opportunities, Covid-19 Impact Analysis)
- To strategically analyse micromarkets with respect to individual growth trends, prospects, and contributions to the overall benign prostatic hyperplasia treatment market
- To analyse market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of the market segments in four geographical regions, namely, North America, Europe, the Asia Pacific, and Rest of the World.
- To profile the key players and comprehensively analyse their product portfolios, market positions, and core competencies.
- To track and analyse competitive developments such as product launches and approvals, partnerships, expansions, and acquisitions in the benign prostatic hyperplasia treatment market
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
Geographic Analysis
- Further breakdown of the benign prostatic hyperplasia treatment market into specific countries/regions in the Rest of Europe and the Rest of Asia Pacific.
Company Information
- Detailed analysis and profiling of additional market players (up to 3) inclusive of:
- Business Overview
- Financial Information
- Product Portfolio
- Developments (last three years)
Generating Response ...
Growth opportunities and latent adjacency in Benign Prostatic Hyperplasia Treatment Market